DistantNews
Support us
Eisai to expand UK Lecanemab production facility with 97 billion won investment
🇰🇷 South Korea /Economy & Trade

Eisai to expand UK Lecanemab production facility with 97 billion won investment

From Chosun Ilbo · () Korean

Translated from Korean, summarized and contextualized by DistantNews.

At a glance

News Sources not specified New plan
  • Japanese pharmaceutical company Eisai plans to expand its production and packaging facilities for the Alzheimer's drug Lecanemab in the UK.
  • The company will invest approximately 48 million pounds (about 97.3 billion won) in its Hatfield facility.
  • This expansion is supported by the UK government's manufacturing development subsidies.

Japanese pharmaceutical firm Eisai is set to expand its production and packaging facilities for the Alzheimer's treatment Lecanemab in the United Kingdom. The company announced plans to invest approximately 48 million pounds, equivalent to about 97.3 billion Korean won, into its existing plant located in Hatfield, Hertfordshire, north of London.

This significant investment is bolstered by subsidies from the UK government's initiative to foster manufacturing growth. The expansion aims to increase the capacity for producing and packaging Lecanemab, a drug developed by Eisai and Biogen, which targets the underlying pathology of Alzheimer's disease.

The move underscores Eisai's commitment to scaling up the supply of Lecanemab to meet anticipated global demand. The drug, also known by its ingredient name lecanemab, has shown promise in slowing cognitive decline in patients with early-stage Alzheimer's.

DistantNews Editorial

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog